INTRODUCTION
Several previous studies have reported the association between serum androgens and prostate cancer. Some studies have shown that low serum androgen levels are related to poor prognosis in men with advanced prostate cancer (Chodak et al., 1991; Imamoto et al., 2001) , high biochemical relapse in patients who underwent prostatectomy (Yamamoto et al., 2007; Roder et al., 2012) , and higher prostate cancer incidence in men who underwent prostate needle biopsy (Hoffman et al., 2000; Karamanolakis et al., 2006; Muller et al., 2012) .
Previously, steroid hormones, such as androgens were measured using radioimmunoassay (RIA) techniques (Hoffman et al., 2000; Karamanolakis et al., 2006) . The disadvantages of RIAs are their low specificity because of cross-reactivity with related hormones and disagreement between different assays (Yamashita et al., 2009; Grebe & Singh, 2011) . Because of the recent and important advancements in the methods of liquidchromatography tandem mass spectrometry (LC-MS/MS), the measurement of androgen levels, including testosterone (T) and dihydrotestosterone (DHT), is now more reliable (Yamashita et al., 2009) .
Recently, Gleason 6 (3 + 3) prostate cancer has become the most commonly diagnosed prostate cancer and is associated with the most favorable prognosis (Eggener et al., 2015) . Epstein and colleagues reported that using a time horizon of 10-15 years, <3% of men diagnosed with a Gleason score of 6 will die as a result of prostate cancer whether treated or not (Carter et al., 2012) . A tumor with a pure Gleason score of 6 is exceedingly unlikely to cause harm in the near future (Kulac et al., 2015) . Therefore, close attention should be paid to the possibility of overdetection and overtreatment for prostate cancer with a Gleason score of 6. In this study, we measured the androgen (T and DHT) levels in the blood of men with a total prostate-specific antigen (PSA) range of 3-10 ng/mL who were subjected to initial prostate biopsy for suspected prostate cancer, using LC-MS/MS. We aimed to differentiate men with benign prostatic hyperplasia or cancer with a Gleason score of 6, who were at risk of overtreatment, from men with cancer with a Gleason score of 7 or more, using serum androgen levels before biopsy.
MATERIALS AND METHODS

Patients
A total of 359 patients with suspected prostate cancer underwent prostate needle biopsy for primary pathological diagnosis at major cancer treatment facilities in Japan between April 2000 and July 2003. All blood samples were collected between 09.00 and 15.00 h to minimize the effect of daily androgen variations. There were 197 men with a total PSA range of 3-10 ng/ mL. Of these, 40 patients were excluded from the analysis because of missing data for free to total PSA ratio. Data for the remaining 157 men who underwent prostate needle biopsy were analyzed.
Biological samples and measurement of androgen levels in blood Serum samples were separated from blood and stored at À70°C until analysis. Serum androgen (T and DHT) levels were determined by LC-MS/MS, as described by Yamashita et al. (2009) .
Chemicals and materials
We purchased T, 5a-dihydrotestosterone, [16,16,17a-2 H 3 ]-T (T-d 3 ), and [16,16,17a-2 H 3 ]-DHT (DHT-d 3 ) from Sigma-Aldrich (St. Louis, MO, USA). The Bond Elut C 18 cartridge was purchased from Varian (Palo Alto, CA, USA), and 4-dimethylaminopyridine (DAP), 2-methyl-6-nitrobenzoic anhydride (MNBAn), and picolinic acid (PA) were purchased from Tokyo Kasei Industry (Tokyo, Japan). Triethylamine was purchased from Wako Pure Chemical Industries (Osaka, Japan). The Cadenza CD C-18 columns and CAPCELL PAK SCX UG80 pre-columns were purchased from Intact (Kyoto, Japan) and Shiseido (Tokyo, Japan), respectively. The derivatization reagent was prepared as follows: 10 mg of DAP, 20 mg of MNBAn, and 25 mg of PA were dissolved into 1 mL of tetrahydrofuran, and then agitated until the mixture became cloudy or crystals appeared. After 3-5 min, the reagent solution was used (Yamashita et al., 2009) . Serum PSA levels were measured using a DPC Imrise third generation PSA assay kit (Nippon DPC corporation, Tokyo, Japan).
LC-MS/MS
Androgen (T and DHT) levels in blood samples were measured using an API-5000 triple-stage quadrupole mass spectrometer (Applied Biosystems, Foster City, CA, USA) connected to a Shimadzu LC-20 AD pump and Shimadzu SIL HTC autosampler (Kyoto, Japan) and an electrospray ionization (ESI) ion source device.
The columns were a CAPCELL PAK SCX UG80 pre-column (35 mm 9 2 mm I.D., particle size 5 lm) and a Cadenza CD-C 18 analytical column (150 mm 9 3 mm I.D., particle size 3 lm), which had been maintained at 40°C.
The mobile phase consisted of CH 3 CN-MeOH (50:50, v/v) (solvent A) and 0.1% formic acid (solvent B). For gradient elution, solvents A/B were used as 60/40 to 90/10 between 0 and 5.0 min and 90/10 to 100/0 between 5.0 and 7.0 min. Solvent A alone was used between 7.0 and 9.0 min. Solvents A/B were used as 100/0 to 60/40 between 9.0 and 11 min. The flow rate was 0.4 mL/min. The following ESI conditions were used: spray voltage, 3300 V; collision gas, nitrogen, 45 psi; curtain gas, 11 psi; ion source temperature, 600°C; and ion polarity, positive.
Histopathology
All prostate biopsy samples were reviewed by a central pathologist. Pathological grading was performed according to the Gleason classification system based on the 2005 International society of Urological Pathology Consensus (ISUP 2005; Epstein et al., 2005) . Histological diagnoses were made by the central pathologist blinded to the association with androgen levels in the blood.
Statistical analysis
We compared clinical factors namely age, total PSA, free PSA, free to total PSA ratio, prostate volume, PSA density, serum DHT, and serum T levels using Spearman's rank correlation coefficient. If some factors were correlated with others, the correlated factors were not analyzed simultaneously because of multicollinearity.
We used the Mann-Whitney U-test to compare the characteristics among patients without cancer, patients with cancer with a Gleason score of 6, and patients with cancers with a Gleason score of 7-10. We used the Hosmer-Lemeshow test to assess the goodness of fit for the logistic regression model. Then, we analyzed the predictors of benign prostatic hyperplasia or cancers with a Gleason score of 6 by univariate and multivariate analyses using a logistic regression analysis. Relative risks and 95% confidence intervals (CIs) were derived. All variables were analyzed as continuous variables. The optimal cutoff point of serum DHT to predict benign prostatic hyperplasia or Gleason 6 prostate cancer was defined as the point with the most significant (Fisher's exact test) split using the web-based tool 'cut off finder' (Budczies et al., 2012) .
All data were analyzed using IBM SPSS version 22 software (IBM Corp., Armonk, NY, USA) and the R Stats Package (R Foundation for Statistical Computing, Vienna, Austria). Each test was twosided, and p < 0.05 was considered significant.
Ethics
Informed consent was obtained from all patients, and the experimental procedures were conducted in accordance with the ethical standards of the Helsinki Declaration. This study was approved by the institutional review board of Yokohama City University.
RESULTS
Patient characteristics are shown in Table 1 . Median age, PSA values, and prostate volume (measured by ultrasound) were 67.0 years, 5.7 ng/mL and 31.4 cm 3 , respectively. Median level of T and DHT in blood was 3798.7 pg/mL (range: 1455.6-8846.2 pg/mL) and 371.7 pg/mL (range: 91.5-881.8 pg/mL), respectively. We analyzed the correlation among all the clinical factors ( Table 2 ). There were strong correlations between prostate volume and PSA density (rs = À0.735), free PSA and free to total PSA ratio (rs = 0.743), and serum T and serum DHT (rs = 0.701). These correlated factors were not analyzed simultaneously because of multicollinearity. Of all 157 patients, benign prostatic hyperplasia was diagnosed in 97 patients (61.8%) and prostate cancer was diagnosed in 60 (38.2%) patients, including 31 (19.7%) patients with a Gleason score of 6 and 29 (18.5%) patients with a Gleason score of 7-10.
The area under the receiver operating characteristics curve (AUC) of individual parameters for predicting benign prostatic hyperplasia or cancer with a Gleason score of 6 are shown in Table 3 . For predicting benign prostatic hyperplasia or cancer with a Gleason score of 6, the AUC of age, total PSA, free PSA, 264 Andrology, 2017, 5, 262-267 free to total PSA ratio, prostate volume, PSA density, serum DHT, and serum T were 0. 67, 0.57, 0.58, 0.64, 0.67, 0.68, 0.67, and 0.65, respectively. We performed the Hosmer-Lemeshow test to assess the goodness of fit for the logistic regression model. The resulting p-value was 0.409, which indicated a good logistic regression model fit. Univariate and multivariate analysis to predict the probability of benign prostatic hyperplasia or cancer with a Gleason score of 6 are also shown in Table 3 . In univariate analysis, age (OR: 0.92, 95% CI: 0.87-0.98, p = 0.014), prostate volume (OR: 1.05, 95% CI: 1.01-1.10, p = 0.009), PSA density (910, OR: 0.49, 95% CI: 0.34-0.72, p < 0.001), serum T (/1000, OR: 1.54, 95% CI: 1.08-2.20, p = 0.016), and serum DHT (/100, OR: 1.55, 95% CI: 1.14-2.11, p = 0.005) were significant predictors of benign prostatic hyperplasia or cancer with a Gleason score of 6.
In multivariate logistic regression models, age (OR: 0.89, 95% CI: 0.82-0.96, p = 0.004), prostate volume (OR: 1.07, 95% CI: 1.02-1.13, p = 0.010), and serum DHT (/100, OR: 1.81, 95% CI: 1.22-2.69, p = 0.003) were statistically significant predictors of benign prostatic hyperplasia or cancer with a Gleason score of 6.
The AUC of the base model (age, PSA, free to total PSA, and prostate volume) was 0.75. The AUC of the base model plus DHT was 0.81. The addition of DHT to the base model improved AUC compared with the base model, although DHT only had a small additive effect on the prediction of benign prostatic hyperplasia or Gleason 6 cancer in this setting. The DHT cutoff point to predict benign prostatic hyperplasia or cancer with a Gleason score of 6 was established at 444.8 pg/mL, with sensitivity, specificity, positive predictive value, and negative predictive value of 36.7, 93.1, 95.9, and 25.0%, respectively.
DISCUSSION
Several studies have reported an association between serum androgen concentrations in blood and the risk of prostate cancer at biopsy. Hoffman et al. (2000) reported that low free T indicated increased incidence of biopsy resulting in a Gleason score of 8 or greater (11 vs. 0%, p = 0.025) in men with PSA levels between 0.9 and 1719 ng/mL. Karamanolakis et al. (2006) reported that T in prostate cancer was lower than in men without prostate cancer (median: 3.4 vs. 5.0, p = 0.0001) with PSA levels of 3-10 ng/mL. Morgentaler & Rhoden (2006) reported that low T indicated higher incidence of prostate cancer (21 vs. 12%, p = 0.04) in men with PSA levels < 4 ng/mL. Rhoden et al. (2008) reported that T/PSA ratio in men with prostate cancer was lower than in men without prostate cancer (mean: 2.85 vs. 1.41, p < 0.01) with PSA levels < 4 ng/mL and symptomatic hypogonadism. Garcia-Cruz et al. (2012) reported that low T was associated with high risk of D'Amico classification (low risk: 470; intermediate risk: 445; high risk: 365, p = 0.03) and T (p = 0.038) and age (p = 0.000) were related to D'Amico risk by multivariate analysis.
Although many reports have discussed the correlation between blood androgen levels and cancer risk at biopsy, previous studies of androgen measurements have had several issues, including methodological accuracy and concerns about confounding factors. Many studies used immunoassays for androgen measurements, but such assays are susceptible to crossreactivity with other steroid hormones because of structural similarity between the hormones (Taieb et al., 2003; Buttler et al., 2015) . To resolve the issues mentioned above, we measured androgen levels using LC-MS/MS. The improved LC-MS/MS is more precise because of its greater sensitivity and specificity (Chadwick et al., 2005; Hsing et al., 2007) . Moreover, to exclude the effect of confounding factors, we performed multivariate analysis after controlling for confounding variables.
Our study showed that high serum DHT levels examined by LC-MS/MS were significantly correlated with the detection of benign prostatic hyperplasia or Gleason 6 prostate cancer in men with PSA levels of 3-10 ng/mL by multivariate analysis. However, Muller et al. (2012) reported that serum DHT levels determined by LC-MS/MS were unrelated to prostate cancer detection or cancer grade in the REDUCE trial. The reasons for this discrepancy are unknown, but could be explained by factors such as distinct study populations, racial differences, and the fact that men with positive biopsies were removed from the REDUCE trial.
Our study showed that serum DHT was significantly high in benign prostatic hyperplasia or Gleason 6 cancer. However, serum DHT levels alone will provide no advantage for predicting benign prostatic hyperplasia or Gleason 6 cancer in a clinical setting. We propose that serum androgen measured by LC-MS/ MS combined with other factors may be a useful tool for the detection of benign prostatic hyperplasia or Gleason 6 cancer and may contribute to prevent the overdetection of insignificant cancer. In our study, the addition of DHT to the base model (age, PSA, free to total PSA, and prostate volume) improved the AUC compared with the base model. Serum DHT could help to distinguish the patients with more indolent disease, which would be useful for selecting suitable patients for active surveillance from those with more aggressive disease.
A limitation of this study is the fact that the study was retrospective and the number of patients was small. Gleason score upgrading may occur between prostate biopsies and prostatectomies in almost 30% of the cases (Chun et al., 2006) . Unfortunately, true Gleason scores of all the prostate specimens obtained from prostatectomies were not investigated in this study. Further prospective studies with large number of patients and longer follow-up are warranted to confirm the validity of high blood DHT levels as predictors of benign prostatic hyperplasia or Gleason 6 cancer. Comparison between serum DHT levels and Gleason score of surgical prostate specimens will also be needed for the validation of these results. In our study, we could not follow-up patients' outcome and prognosis. In a future confirmatory study, not only the association of serum DHT with cancer aggressiveness, but also with cancer prognosis, might be evaluated.
In conclusion, we confirmed that high dihydrotestosterone blood levels can predict benign prostatic hyperplasia or prostate cancer with a Gleason score of 6 in men with prostate-specific antigen levels of 3-10 ng/mL. Based on our study results, serum dihydrotestosterone levels would be helpful in predicting benign prostatic hyperplasia or Gleason 6 cancer before biopsy and might be valuable for patient counseling at the prostate biopsy stage.
